{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:04:43Z","timestamp":1762254283254,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H23-GanRinsho-Ippan-020","the Ministry of Health","Labor","Welfare of Japan"],"award-info":[{"award-number":["H23-GanRinsho-Ippan-020","the Ministry of Health","Labor","Welfare of Japan"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["Japan Agency for Medical Research","Development","18ck0106338s0502"],"award-info":[{"award-number":["Japan Agency for Medical Research","Development","18ck0106338s0502"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12185-022-03473-y","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T11:03:05Z","timestamp":1667041385000},"page":"206-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2954-5691","authenticated-orcid":false,"given":"Yoshitaka","family":"Imaizumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Iwanaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kisato","family":"Nosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ishitsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naokuni","family":"Uike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Tokura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Uchimaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"3473_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","volume":"50","author":"T Uchiyama","year":"1977","unstructured":"Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481\u201392.","journal-title":"Blood"},{"key":"3473_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984\u201387). Br J Haematol. 1991;79:428\u201337.","journal-title":"Br J Haematol"},{"key":"3473_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12185-018-02588-5","volume":"109","author":"K Tsukasaki","year":"2019","unstructured":"Tsukasaki K, Fukushima T. JSH practical guidelines for hematological malignancies 2018; II. Lymphoma-8 Adult T cell leukemia-lymphoma. Int J Hematol. 2019;109:249\u201359.","journal-title":"Int J Hematol"},{"key":"3473_CR4","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1182\/blood-2009-09-242347","volume":"115","author":"Y Takasaki","year":"2010","unstructured":"Takasaki Y, Iwanaga M, Imaizumi Y, Tawara M, Joh T, Kohno T, et al. Long-term study of indolent adult T cell leukemia-lymphoma. Blood. 2010;115:4337\u201343.","journal-title":"Blood"},{"key":"3473_CR5","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s12185-019-02602-4","volume":"109","author":"H Taniguchi","year":"2019","unstructured":"Taniguchi H, Imaizumi Y, Takasaki Y, Nakashima J, Kato T, Itonaga H, et al. Clinical features at transformation in adult T cell leukemia-lymphoma with smoldering and chronic types. Int J Hematol. 2019;109:402\u20138.","journal-title":"Int J Hematol"},{"key":"3473_CR6","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1111\/cas.13398","volume":"108","author":"K Nosaka","year":"2017","unstructured":"Nosaka K, Iwanaga M, Imaizumi Y, Ishitsuka K, Ishizawa K, Ishida Y, et al. Epidemiological and clinical features of adult T cell leukemia-lymphoma in Japan, 2010\u20132011: a nationwide survey. Cancer Sci. 2017;108:2478\u201386.","journal-title":"Cancer Sci"},{"key":"3473_CR7","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1111\/cas.14658","volume":"111","author":"Y Imaizumi","year":"2020","unstructured":"Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, et al. Prognosis of patients with adult T cell leukemia\/lymphoma in Japan: a nationwide hospital-based study. Cancer Sci. 2020;111:4567\u201380.","journal-title":"Cancer Sci"},{"key":"3473_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2017-01-757542","volume":"130","author":"H Katsuya","year":"2017","unstructured":"Katsuya H, Shimokawa M, Ishitsuka K, Kawai K, Amano M, Utsunomiya A, et al. Prognostic index for chronic- and smoldering-type adult T cell leukemia-lymphoma. Blood. 2017;130:39\u201347.","journal-title":"Blood"},{"key":"3473_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1200\/JCO.18.00501","volume":"37","author":"LB Cook","year":"2019","unstructured":"Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised adult T cell leukemia-lymphoma international consensus meeting report. J Clin Oncol. 2019;37:677\u201387.","journal-title":"J Clin Oncol"},{"key":"3473_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature18294","volume":"534","author":"K Kataoka","year":"2016","unstructured":"Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, et al. Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers. Nature. 2016;534:402\u20136.","journal-title":"Nature"},{"key":"3473_CR11","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1038\/s41467-021-25101-9","volume":"12","author":"M Yamagishi","year":"2021","unstructured":"Yamagishi M, Kubokawa M, Kuze Y, Suzuki A, Yokomizo A, Kobayashi S, et al. Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma. Nat Commun. 2021;12:4821.","journal-title":"Nat Commun"},{"key":"3473_CR12","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","volume":"28","author":"A Bazarbachi","year":"2010","unstructured":"Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T cell leukemia\/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177\u201383.","journal-title":"J Clin Oncol"},{"key":"3473_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2017-01-761874","volume":"131","author":"K Kataoka","year":"2018","unstructured":"Kataoka K, Iwanaga M, Yasunaga JI, Nagata Y, Kitanaka A, Kameda T, et al. Prognostic relevance of integrated genetic profiling in adult T cell leukemia\/lymphoma. Blood. 2018;131:215\u201325.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03473-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03473-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03473-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T16:59:37Z","timestamp":1675184377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03473-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["3473"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03473-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2022,10,29]]},"assertion":[{"value":"19 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kisato Nosaka reports consulting fees from Kyowa Kirin and honoraria from Celgene, Meiji Seka Pharma, Janssen Pharmaceutical, Bristol Myers Squbb, Abbie, Daiichi Sankyo, and Novartis. Kenji Ishitsuka reports grants from Ono Pharmaceutical and Kyowa Kirin, consulting fees from Daiichi-Sankyo, and honoraria from Chugai Pharmaceutical and Meiji Seika Pharma. Kenichi Ishizawa reports grants from SymBio, IQVIA, Novartis, Abbie, Zenyaku, and Otsuka Pharmaceutical, consulting fees from SAWAI, Micron, and Kyowa Kirin, and honoraria from Novartis, Takeda, Bristol Myers Squbb, Ono Pharmaceutical, Chugai Pharmaceutical, Eisai, and Janssen Pharmaceutical. Atae Utsunomiya reports consulting fees from JIMRO and Otsuka Medical Devices and honoraria from Bristol Myers Squbb and Meiji Seka Pharma. Koichi Oshima reports honoraria from Chugai Pharmaceutical, Kyowa Kirin, and Takeda. Kuhnihiro Tsukasaki reports consulting fees from Ono Pharmaceutical, Meiji Seka Pharma, Yakuruto, Solasia Pharma, Meiji Seika Pharma, and HUYABIO, honoraria from Chugai Pharmaceutical, Eizai, and Meiji Seika Pharma, and research funding from Kyowa Kirin, Meiji Seika Pharma, Celgene, Byer, Daiich-Sankyo, HUYABIO, and Regeneron Pharmaceuticals. All remaining authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}